Mersana Therapeutics, Inc.
MRSN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11 | $3 | $3 | $16 |
| % Growth | 260.2% | 11% | -83.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $11 | $3 | $3 | $16 |
| % Margin | 100% | 90.6% | 100% | 100% |
| R&D Expenses | $12 | $16 | $18 | $22 |
| G&A Expenses | $6 | $7 | $9 | $9 |
| SG&A Expenses | $6 | $7 | $9 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $18 | $23 | $27 | $31 |
| Operating Income | -$7 | -$21 | -$25 | -$15 |
| % Margin | -67.9% | -673.3% | -890.1% | -90.5% |
| Other Income/Exp. Net | -$0 | -$4 | $0 | $1 |
| Pre-Tax Income | -$8 | -$24 | -$24 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$24 | -$24 | -$14 |
| % Margin | -68.5% | -795% | -875.9% | -86.3% |
| EPS | -1.51 | -4.87 | -4.85 | -2.86 |
| % Growth | 69% | -0.4% | -69.6% | – |
| EPS Diluted | -1.51 | -4.87 | -4.85 | -2.86 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 5 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$23 | -$23 | -$13 |
| % Margin | -64.2% | -763.6% | -836.3% | -78.3% |